Literature DB >> 15810091

Clinicopathological significance of heparanase and basic fibroblast growth factor expression in human esophageal cancer.

Biao Han1, Jian Liu, Min-Jie Ma, Lin Zhao.   

Abstract

AIM: Human heparanase is an endo-D-glucuronidase that degrades heparan sulfate/heparin and has been implicated in a variety of biological processes. The objective was to investigate the expression of heparanase (Hps) and basic fibroblast growth factor (bFGF) and their relationship to neoangiogenesis and metastasis of human esophageal carcinoma.
METHODS: Seventy-nine patients who had undergone esophageal resection for esophageal carcinoma without preoperative treatment were included in the present study. Immunohistochemistry was used to study the expression of Hps, bFGF and microvessel density (MVD) in 79 cases of esophageal carcinoma. bFGF and Hps were quantitatively detected with immunohistochemistry in 79 cases of human esophageal carcinoma and 19 cases of adjacent normal human esophageal carcinoma. Cd34 was used to explore the MVD as a marker of endothelial cells.
RESULTS: Hps and bFGF expression in tumor tissue, being remarkably higher than that in normal esophageal tissue, were significantly correlated with clinicopathological features (depth of invasion, lymph-node metastasis and TNM stage) and MVD.
CONCLUSION: The results of this study suggest that the coexpression of Hps and bFGF plays a key role in angiogenesis, invasion and metastasis of esophageal carcinoma. Hps and bFGF may serve as a predictor of progression in esophageal carcinoma. The expression of heparanase in esophageal carcinoma enhances growth, invasion, and angiogenesis of the tumor, and bFGF seems to be a potent antigenic factor for esophageal carcinoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15810091      PMCID: PMC4305794          DOI: 10.3748/wjg.v11.i14.2188

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  33 in total

1.  A rapid quantitative assay for the detection of mammalian heparanase activity.

Authors:  C Freeman; C R Parish
Journal:  Biochem J       Date:  1997-07-01       Impact factor: 3.857

2.  Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation.

Authors:  A C Rapraeger; A Krufka; B B Olwin
Journal:  Science       Date:  1991-06-21       Impact factor: 47.728

Review 3.  Proteoglycans: structures and interactions.

Authors:  L Kjellén; U Lindahl
Journal:  Annu Rev Biochem       Date:  1991       Impact factor: 23.643

4.  Basic fibroblast growth factor induces angiogenesis in vitro.

Authors:  R Montesano; J D Vassalli; A Baird; R Guillemin; L Orci
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

Review 5.  Growth factors in the extracellular matrix.

Authors:  J Taipale; J Keski-Oja
Journal:  FASEB J       Date:  1997-01       Impact factor: 5.191

6.  Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis.

Authors:  M D Hulett; C Freeman; B J Hamdorf; R T Baker; M J Harris; C R Parish
Journal:  Nat Med       Date:  1999-07       Impact factor: 53.440

Review 7.  The coordinated regulation of heparan sulfate, syndecans and cell behavior.

Authors:  A C Rapraeger
Journal:  Curr Opin Cell Biol       Date:  1993-10       Impact factor: 8.382

Review 8.  The biology of perlecan: the multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices.

Authors:  R V Iozzo; I R Cohen; S Grässel; A D Murdoch
Journal:  Biochem J       Date:  1994-09-15       Impact factor: 3.857

9.  Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor.

Authors:  A Yayon; M Klagsbrun; J D Esko; P Leder; D M Ornitz
Journal:  Cell       Date:  1991-02-22       Impact factor: 41.582

Review 10.  Heparanases and tumor metastasis.

Authors:  M Nakajima; T Irimura; G L Nicolson
Journal:  J Cell Biochem       Date:  1988-02       Impact factor: 4.429

View more
  6 in total

1.  High expression of heparanase is significantly associated with dedifferentiation and lymph node metastasis in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA and via HIF1a to HB-EGF and bFGF.

Authors:  Andreas-Claudius Hoffmann; Ryutaro Mori; Daniel Vallbohmer; Jan Brabender; Uta Drebber; Stephan E Baldus; Ellen Klein; Mizutomo Azuma; Ralf Metzger; Christina Hoffmann; Arnulf H Hoelscher; Kathleen D Danenberg; Klaus L Prenzel; Peter V Danenberg
Journal:  J Gastrointest Surg       Date:  2008-08-13       Impact factor: 3.452

2.  Genetics in the pathogenesis of esophageal cancer: possible predictive and prognostic factors.

Authors:  Daniel Vallböhmer; Jan Brabender; Ralf Metzger; Arnulf H Hölscher
Journal:  J Gastrointest Surg       Date:  2009-09-12       Impact factor: 3.452

3.  Association of angiogenic factors with prognosis in esophageal cancer.

Authors:  Lena Dreikhausen; Susanne Blank; Leila Sisic; Ulrike Heger; Wilko Weichert; Dirk Jäger; Thomas Bruckner; Natalia Giese; Lars Grenacher; Christine Falk; Katja Ott; Thomas Schmidt
Journal:  BMC Cancer       Date:  2015-03-13       Impact factor: 4.430

4.  Inflammatory cytokines are associated with response and prognosis in patients with esophageal cancer.

Authors:  Susanne Blank; Henrik Nienhüser; Lena Dreikhausen; Leila Sisic; Ulrike Heger; Katja Ott; Thomas Schmidt
Journal:  Oncotarget       Date:  2017-07-18

5.  Effect of the Rehabilitation Program, ReStOre, on Serum Biomarkers in a Randomized Control Trial of Esophagogastric Cancer Survivors.

Authors:  Susan A Kennedy; Stephanie L Annett; Margaret R Dunne; Fiona Boland; Linda M O'Neill; Emer M Guinan; Suzanne L Doyle; Emma K Foley; Jessie A Elliott; Conor F Murphy; Annemarie E Bennett; Michelle Carey; Daniel Hillary; Tracy Robson; John V Reynolds; Juliette Hussey; Jacintha O'Sullivan
Journal:  Front Oncol       Date:  2021-09-15       Impact factor: 6.244

Review 6.  Cytokines association with clinical and pathological changes in esophageal squamous cell carcinoma.

Authors:  Dorota Diakowska
Journal:  Dis Markers       Date:  2013       Impact factor: 3.434

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.